[{"NetIncomeLoss_1_Q2_USD":-11127000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":3712000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":3603193.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":3978054.0,"InterestAndOtherIncome_2_Q2_USD":30000.0,"InterestAndOtherIncome_1_Q2_USD":13000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":4786000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-2066000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":7499000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":0.0,"StockIssuedDuringPeriodValueConversionOfUnits_2_Q2_USD":50000000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":160309674.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":160309674.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q2_USD":42000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_2_Q2_USD":84000.0,"CommonStockSharesIssued_0_Q2_shares":5700000.0,"Assets_0_Q2_USD":120097000.0,"ShareBasedCompensation_2_Q2_USD":1061000.0,"AssetsCurrent_0_Q2_USD":118431000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0,"DepreciationAndAmortization_2_Q2_USD":48000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":112729000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":6818000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-970000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-118000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-142000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":0.0,"IncomeTaxExpenseBenefit_1_Q2_USD":0.0,"ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_2_Q2_USD":0.0,"CommonStockValue_0_Q2_USD":536000.0,"Liabilities_0_Q2_USD":7435000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":-663000.0,"PreferredStockDividendRatePercentage_2_Q2_pure":0.08,"NetIncomeLossAvailableToCommonStockholdersBasic_2_Q2_USD":-24402000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q2_USD":-11127000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-24402000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-11127000.0,"AccruedEmployeeBenefitsCurrent_0_Q2_USD":1321000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":787000.0,"CommonUnitAuthorized_0_Q2_shares":165393580.0,"SharesIssuedPricePerShare_0_Q2_USD":2.0854,"ResearchAndDevelopmentExpense_2_Q2_USD":15855000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":2249000.0,"OperatingIncomeLoss_2_Q2_USD":-23354000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-10659000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-24775000.0,"LiabilitiesCurrent_0_Q2_USD":7408000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-27504000.0,"AccountsPayableCurrent_0_Q2_USD":2622000.0,"NonoperatingIncomeExpense_2_Q2_USD":-98000.0,"NonoperatingIncomeExpense_1_Q2_USD":-129000.0,"InterestExpense_2_Q2_USD":10000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-23452000.0,"InterestExpense_1_Q2_USD":0.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":414000.0,"InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_0_Q2_USD":1360000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":112729000.0,"MembersEquity_0_Q2_USD":-69365000.0,"OtherAccruedLiabilitiesNoncurrent_0_Q2_USD":27000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":15000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":306000.0,"NetIncomeLoss_2_Q2_USD":-24402000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":5702000.0,"PaymentsToAcquireInterestInJointVenture_2_Q2_USD":2000000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":-468000.0,"PaymentsToAcquireEquityMethodInvestments_1_Q2_USD":1500000.0,"OperatingIncomeLoss_1_Q2_USD":-10530000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":120097000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":1061000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":539000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_Q2_shares":0.0,"OperatingExpenses_2_Q2_USD":23354000.0,"OperatingExpenses_1_Q2_USD":10530000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-2.8,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":-950000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-6.77,"DeferredOfferingCosts_0_Q2_USD":2400000.0,"StockholdersEquity_0_Q2_USD":-69365000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":66000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-71416000.0,"DividendsPreferredStock_2_Q2_USD":0.0,"DividendsPreferredStock_1_Q2_USD":0.0,"CommonStockSharesOutstanding_0_Q2_shares":5700000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":2000000.0,"ProfitLoss_2_Q2_USD":-24402000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":1628000.0,"Ticker":"RLYB","CIK":"1739410","name":"RALLYBIO CORP","OfficialName":"Rallybio Corporation Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"312955648.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210909"}]